药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Betaprodine
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Baricitinib.
Betaprodine
Tecemotide
The therapeutic efficacy of Tecemotide can be decreased when used in combination with Baricitinib.
Betaprodine
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Baricitinib.
Betaprodine
Human rabies virus immune globulin
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Baricitinib.
Betaprodine
Hepatitis A Vaccine
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Baricitinib.
Betaprodine
Typhoid Vi polysaccharide vaccine
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Baricitinib.
Betaprodine
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Baricitinib.